Targeted Innovation in Biliary Tract Cancer: The COMPANION-002 Trial Results on October 24, 2026 Posted by
The Recovery Paradox: Why Your Post-Workout Routine Might Be Holding You Back on October 24, 2026 Posted by
Unmasking the Invisible: New Immune Cell Discovery Offers Hope Against Aggressive Lung Cancer on October 24, 2026 Posted by
Unveiling a New Horizon in Mobility: UPnRIDE and Kessler Foundation Forge Groundbreaking Research Partnership on October 24, 2026 Posted by
Empowering the Next Generation: Active Minds Unveils the 2026-2027 Student Advisory Committee Cohort on October 24, 2026 Posted by
The New Era of Bipolar Care: How Recent Breakthroughs in Science are Redefining "Living Well" on October 24, 2026 Posted by
The Hidden Calorie Spike: Why Your Morning Coffee is Becoming Less "Black" on October 24, 2026 Posted by
Targeted Innovation in Biliary Tract Cancer: The COMPANION-002 Trial Results on October 24, 2026 Posted by
The Recovery Paradox: Why Your Post-Workout Routine Might Be Holding You Back on October 24, 2026 Posted by
Unmasking the Invisible: New Immune Cell Discovery Offers Hope Against Aggressive Lung Cancer on October 24, 2026 Posted by
Unveiling a New Horizon in Mobility: UPnRIDE and Kessler Foundation Forge Groundbreaking Research Partnership on October 24, 2026 Posted by
Posted in Medical Innovations A Legacy of Transformation: Andy Plump to Depart Takeda Following Decade of R&D Reimagining on September 11, 2026
Posted in Medical Innovations Takeda’s Mimrylo Approval Marks a Paradigm Shift in Polycythemia Vera Treatment on August 31, 2026
Posted in Sleep Health Breakthrough in Narcolepsy Treatment: Analyzing the Clinical and Economic Impact of Takeda’s Oveporexton on August 23, 2026
Posted in Medical Innovations A New Dawn for Narcolepsy: Takeda’s Orzeyful Signals a Paradigm Shift in Sleep Medicine on August 6, 2026
Posted in Sleep Health Breakthrough in Narcolepsy Treatment: Takeda’s Oveporexton Shows Promise in Phase 3 Clinical Trials on July 6, 2026
Posted in Sleep Health A New Dawn for Narcolepsy: Takeda’s Oveporexton Shows Transformative Potential in Phase 3 Trials on June 24, 2026
Posted in Sleep Health Beyond Symptom Management: Takeda’s Oveporexton Shows Promise in Redefining Narcolepsy Type 1 Treatment on June 16, 2026
Posted in Medical Innovations Takeda’s Zasocitinib Challenges the TYK2 Status Quo: A New Horizon for Oral Psoriasis Treatment on June 15, 2026
Posted in Digital Health Tools The $2.6 Billion Verdict: How a ‘Pay-for-Delay’ Settlement Landed Takeda in Antitrust Crosshairs on May 23, 2026 rifanmuazin
Posted in Medical Innovations Takeda Pharmaceuticals Agrees to $13.6 Million Settlement Over Kickback Allegations Involving Trintellix on May 15, 2026 rifanmuazin
